Physician profile
Robert Allen Sable
NPI 1487649554
$25,735.25
in general payments reported to CMS, 2019-2025
40 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,494 · 2020: $1,140 · 2021: $1,947 · 2022: $1,943 · 2023: $2,510 · 2024: $15K · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,350 · Travel and Lodging: $1,320 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,520.00 |
| Food and Beverage | $5,350.36 |
| Travel and Lodging | $1,320.46 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $12,648.89 | 2024 | Voquezna |
| Abbvie INC. | $3,521.79 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,769.45 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $994.20 | 2019-2023 | Vemlidy |
| Janssen Biotech, INC. | $762.61 | 2019-2024 | Stelara, Tremfya |
| Pfizer INC. | $722.26 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $660.14 | 2019-2024 | Entyvio, Hyqvia |
| E.R. Squibb & Sons, L.L.C. | $474.39 | 2021-2024 | Zeposia |
| Genzyme Corporation | $345.01 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $308.93 | 2020-2024 | Ocaliva |
| Celgene Corporation | $285.68 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $213.05 | 2019-2024 | |
| Redhill Biopharma INC. | $186.62 | 2020-2022 | |
| Allergan, INC. | $169.68 | 2019 | |
| Merck Sharp & Dohme LLC | $156.49 | 2019-2024 | Dificid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $148.12 | 2019-2024 | Linzess |
| Shionogi INC | $136.22 | 2019 | |
| Ferring Pharmaceuticals INC. | $128.43 | 2019-2021 | |
| Ardelyx, INC. | $127.26 | 2022-2024 | Ibsrela |
| Olympus America INC. | $119.00 | 2019 | |
| Daiichi Sankyo INC. | $105.58 | 2020-2024 | Injectafer |
| Qol Medical, LLC | $84.65 | 2021-2024 | Sucraid, Sucraid |
| Ucb, INC. | $80.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $80.67 | 2022-2023 | Dupixent |
| Amgen INC. | $76.82 | 2024 | |
| Madrigal Pharmaceuticals | $67.91 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $63.41 | 2023 | Idacio |
| Novo Nordisk INC | $43.11 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $40.44 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $37.70 | 2020 | |
| Ethicon US, LLC | $31.89 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.27 | 2023 | Terlivaz |
| Eisai INC. | $19.10 | 2021 | |
| Organon LLC | $17.83 | 2023 | Hadlima, Renflexis |
| Medtronic, INC. | $17.34 | 2023 | Gi Genius |
| Alnylam Pharmaceuticals INC. | $15.03 | 2023 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $14.32 | 2021 | |
| Intra-Sana Laboratories | $14.30 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Celltrion USA INC. | $13.33 | 2024 | Vegzelma |
| Alfasigma USA, INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.